Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor
Respiratory syncytial virus causes lung infections in children, immunocompromised adults, and in the elderly. Here the authors show that a chemical inhibitor to a viral fusion protein is effective in reducing viral titre and ameliorating infection in rodents and neonatal lambs.
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2017-08-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-017-00170-x |
| id |
doaj-a53af0caadf64c108081ce0c70f541ee |
|---|---|
| record_format |
Article |
| spelling |
doaj-a53af0caadf64c108081ce0c70f541ee2021-01-31T12:37:00ZengNature Publishing GroupNature Communications2041-17232017-08-018111510.1038/s41467-017-00170-xTherapeutic efficacy of a respiratory syncytial virus fusion inhibitorDirk Roymans0Sarhad S Alnajjar1Michael B Battles2Panchan Sitthicharoenchai3Polina Furmanova-Hollenstein4Peter Rigaux5Joke Van den Berg6Leen Kwanten7Marcia Van Ginderen8Nick Verheyen9Luc Vranckx10Steffen Jaensch11Eric Arnoult12Richard Voorzaat13Jack M. Gallup14Alejandro Larios-Mora15Marjolein Crabbe16Dymphy Huntjens17Pierre Raboisson18Johannes P. Langedijk19Mark R. Ackermann20Jason S McLellan21Sandrine Vendeville22Anil Koul23Janssen Infectious Diseases and Vaccines, Janssen Pharmaceutica NVCollege of Veterinary Medicine, Iowa State UniversityDepartment of Biochemistry, Geisel School of Medicine at DartmouthCollege of Veterinary Medicine, Iowa State UniversityJanssen Vaccines and PreventionJanssen Infectious Diseases and Vaccines, Janssen Pharmaceutica NVJanssen Infectious Diseases and Vaccines, Janssen Pharmaceutica NVJanssen Infectious Diseases and Vaccines, Janssen Pharmaceutica NVJanssen Infectious Diseases and Vaccines, Janssen Pharmaceutica NVJanssen Infectious Diseases and Vaccines, Janssen Pharmaceutica NVJanssen Infectious Diseases and Vaccines, Janssen Pharmaceutica NVComputational Biology, Janssen Pharmaceutica NVComputational Chemistry, Janssen R&D LLCJanssen Vaccines and PreventionCollege of Veterinary Medicine, Iowa State UniversityCollege of Veterinary Medicine, Iowa State UniversityNon-Clinical Statistics, Janssen Pharmaceutica NVClinical Pharmacology and Pharmacometrics, Janssen Pharmaceutica NVJanssen Infectious Diseases and Vaccines, Janssen Pharmaceutica NVJanssen Vaccines and PreventionCollege of Veterinary Medicine, Iowa State UniversityDepartment of Biochemistry, Geisel School of Medicine at DartmouthJanssen Infectious Diseases and Vaccines, Janssen Pharmaceutica NVJanssen Infectious Diseases and Vaccines, Janssen Pharmaceutica NVRespiratory syncytial virus causes lung infections in children, immunocompromised adults, and in the elderly. Here the authors show that a chemical inhibitor to a viral fusion protein is effective in reducing viral titre and ameliorating infection in rodents and neonatal lambs.https://doi.org/10.1038/s41467-017-00170-x |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Dirk Roymans Sarhad S Alnajjar Michael B Battles Panchan Sitthicharoenchai Polina Furmanova-Hollenstein Peter Rigaux Joke Van den Berg Leen Kwanten Marcia Van Ginderen Nick Verheyen Luc Vranckx Steffen Jaensch Eric Arnoult Richard Voorzaat Jack M. Gallup Alejandro Larios-Mora Marjolein Crabbe Dymphy Huntjens Pierre Raboisson Johannes P. Langedijk Mark R. Ackermann Jason S McLellan Sandrine Vendeville Anil Koul |
| spellingShingle |
Dirk Roymans Sarhad S Alnajjar Michael B Battles Panchan Sitthicharoenchai Polina Furmanova-Hollenstein Peter Rigaux Joke Van den Berg Leen Kwanten Marcia Van Ginderen Nick Verheyen Luc Vranckx Steffen Jaensch Eric Arnoult Richard Voorzaat Jack M. Gallup Alejandro Larios-Mora Marjolein Crabbe Dymphy Huntjens Pierre Raboisson Johannes P. Langedijk Mark R. Ackermann Jason S McLellan Sandrine Vendeville Anil Koul Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor Nature Communications |
| author_facet |
Dirk Roymans Sarhad S Alnajjar Michael B Battles Panchan Sitthicharoenchai Polina Furmanova-Hollenstein Peter Rigaux Joke Van den Berg Leen Kwanten Marcia Van Ginderen Nick Verheyen Luc Vranckx Steffen Jaensch Eric Arnoult Richard Voorzaat Jack M. Gallup Alejandro Larios-Mora Marjolein Crabbe Dymphy Huntjens Pierre Raboisson Johannes P. Langedijk Mark R. Ackermann Jason S McLellan Sandrine Vendeville Anil Koul |
| author_sort |
Dirk Roymans |
| title |
Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor |
| title_short |
Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor |
| title_full |
Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor |
| title_fullStr |
Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor |
| title_full_unstemmed |
Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor |
| title_sort |
therapeutic efficacy of a respiratory syncytial virus fusion inhibitor |
| publisher |
Nature Publishing Group |
| series |
Nature Communications |
| issn |
2041-1723 |
| publishDate |
2017-08-01 |
| description |
Respiratory syncytial virus causes lung infections in children, immunocompromised adults, and in the elderly. Here the authors show that a chemical inhibitor to a viral fusion protein is effective in reducing viral titre and ameliorating infection in rodents and neonatal lambs. |
| url |
https://doi.org/10.1038/s41467-017-00170-x |
| work_keys_str_mv |
AT dirkroymans therapeuticefficacyofarespiratorysyncytialvirusfusioninhibitor AT sarhadsalnajjar therapeuticefficacyofarespiratorysyncytialvirusfusioninhibitor AT michaelbbattles therapeuticefficacyofarespiratorysyncytialvirusfusioninhibitor AT panchansitthicharoenchai therapeuticefficacyofarespiratorysyncytialvirusfusioninhibitor AT polinafurmanovahollenstein therapeuticefficacyofarespiratorysyncytialvirusfusioninhibitor AT peterrigaux therapeuticefficacyofarespiratorysyncytialvirusfusioninhibitor AT jokevandenberg therapeuticefficacyofarespiratorysyncytialvirusfusioninhibitor AT leenkwanten therapeuticefficacyofarespiratorysyncytialvirusfusioninhibitor AT marciavanginderen therapeuticefficacyofarespiratorysyncytialvirusfusioninhibitor AT nickverheyen therapeuticefficacyofarespiratorysyncytialvirusfusioninhibitor AT lucvranckx therapeuticefficacyofarespiratorysyncytialvirusfusioninhibitor AT steffenjaensch therapeuticefficacyofarespiratorysyncytialvirusfusioninhibitor AT ericarnoult therapeuticefficacyofarespiratorysyncytialvirusfusioninhibitor AT richardvoorzaat therapeuticefficacyofarespiratorysyncytialvirusfusioninhibitor AT jackmgallup therapeuticefficacyofarespiratorysyncytialvirusfusioninhibitor AT alejandrolariosmora therapeuticefficacyofarespiratorysyncytialvirusfusioninhibitor AT marjoleincrabbe therapeuticefficacyofarespiratorysyncytialvirusfusioninhibitor AT dymphyhuntjens therapeuticefficacyofarespiratorysyncytialvirusfusioninhibitor AT pierreraboisson therapeuticefficacyofarespiratorysyncytialvirusfusioninhibitor AT johannesplangedijk therapeuticefficacyofarespiratorysyncytialvirusfusioninhibitor AT markrackermann therapeuticefficacyofarespiratorysyncytialvirusfusioninhibitor AT jasonsmclellan therapeuticefficacyofarespiratorysyncytialvirusfusioninhibitor AT sandrinevendeville therapeuticefficacyofarespiratorysyncytialvirusfusioninhibitor AT anilkoul therapeuticefficacyofarespiratorysyncytialvirusfusioninhibitor |
| _version_ |
1724317158383550464 |